Table 2 Prognostic value of clinical factors and the gene mutation with overall survival in NSCLC treated with ICB.

From: Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB

Variable

Univariate analysis

Multivariate analysis

HR

95% CI

P

HR

95% CI

P

Drug (Combination VS Monotherapy)

0.405

0.206–0.796

0.009

0.401

0.202–0.797

0.009

TMB (High VS Low)

0.971

0.954–0.989

0.001

0.991

0.967–1.016

0.470

EPHA3 (Mutation VS Wild)

0.580

0.354–0.953

0.031

0.717

0.427–1.204

0.209

EPHA5 (Mutation VS Wild)

0.474

0.258–0.869

0.016

0.720

0.366–1.417

0.342

EPHA7 (Mutation VS Wild)

0.337

0.139–0.819

0.016

0.564

0.226–1.408

0.220

MGA (Mutation VS Wild)

0.464

0.229–0.941

0.033

0.678

0.325–1.416

0.301

NTRK3 (Mutation VS Wild)

0.358

0.156–0.805

0.013

0.488

0.206–1.157

0.103

PBRM1 (Mutation VS Wild)

2.098

1.237–3.558

0.006

2.597

1.486–4.537

0.001

PTPRD (Mutation VS Wild)

0.624

0.398–0.979

0.040

0.863

0.514–1.447

0.576

ZFHX3 (Mutation VS Wild)

0.256

0.114–0.577

0.001

0.337

0.145–0.781

0.011

  1. Monotherapy: anti-PD-(L)1 monotherapy; Combination: anti-PD-(L)1 monotherapy in combination with anti-CTLA-4; TMB high: TMB ≥ 10; TMB low: TMB < 10.
Back to article page